Global partnerships COSMED has a track record of distributor agreements and international reach, including a US distribution partnership with Baxter for Q-NRG+ and a network covering more than 80 countries. Target opportunities: expand USD/EU territory coverage, co-market with Baxter or similar distributors, and leverage their global footprint for new metabolic and body composition devices.

Advanced software Recent software milestones include the second generation OMNIA data management platform (launched in late 2021) and strong emphasis on comprehensive metabolic, lung function, and body composition data. Sales approach: position OMNIA-based workflows as a value-add for clinics and research centers, highlighting integration with multiple COSMED devices and ATS/ERS/ACSM-aligned metrics.

Regulatory readiness COSMED maintains EN13485 certification and holds CE, IEC 60601-1/EN 60601-1, FDA 510(K) clearances, signaling strong regulatory competency. Opportunity open for devices nearing market entry or expansion where regulatory support and compliance acceleration can shorten sales cycles and boost confidence in procurement teams.

Diverse product suite Product lineup spans spirometry, pulmonary function tests, metabolic analysis, and body composition assessment, with a history of innovative, portable and desktop devices. Upsell and cross-sell potential across clinics, sports science labs, and healthcare facilities seeking integrated diagnostic ecosystems.

Growth signals Revenue range indicates mid-market scale with global operations and a focus on education, sports science, and research sectors. Leverage this momentum to propose bundled solutions, long-term service agreements, and training packages tailored to research institutions and hospitals investing in metabolic and respiratory diagnostics.